Clinical trials: Type 1 or Type 2 Diabetes
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study for Patients With Diabetes Mellitus (IOPA)
The purpose of this study is to compare glycemic control (HbA1c) in Chinese patients with type 1 or type 2 diabetes when treated with insulin lispro low mixture and human insulin 30/70.
- Trial name
- IOPA (NCT00420095)
- Testing
- Human insulin 30/70, Insulin lispro low mix
- Where
- 4 sites in China
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity, Type 2 Diabetes
Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and…
- Trial name
- T2DM (NCT06615700)
- Testing
- NA-931
- Where
- 2 sites in Australia
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Type 2 Diabetes
A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics
The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics compared to insulin degludec QD for 16 weeks.
- Trial name
- NCT04663282
- Testing
- INS068 injection, Insulin Degludec
- Where
- 35 sites in United States, Australia and 1 more
- Volunteers
- 179 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes, Diabetes Mellitus, Type 2
Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505
The Sponsor, Genfit, has developed a new formulation of GFT505 (60 mg). The objective is to compare the relative bioavailability between the new GFT505 formulation (capsule dosed at 60 mg GFT505) and the old GFT505 formulation…
- Conditions
- Type 2 Diabetes, Diabetes Mellitus, Type 2, Metabolic Diseases, Cardiovascular Diseases
- Trial name
- NCT01474161
- Testing
- GFT505 120mg - old formulation, GFT505 120mg - new formulation, GFT505 180mg - new formulation
- Where
- France
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Genfit
Healthy Volunteers and Diabetes Participants
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2 Diabetes
This is a Phase 1/2 randomized study of oral doses of PAL-119 in healthy volunteers and participants with diabetes.
- Trial name
- NCT07901595
- Testing
- PAL-119
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- Paulex Bio Inc.
Type 1 or Type 2 Diabetes
Bigfoot Unity Real World Study
This study is observational, designed to collect real world use and safety data for those using the Bigfoot Unity Diabetes Management System for 12 months.
- Trial name
- BURST (NCT05088265)
- Testing
- Bigfoot Unity Diabetes Management System
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Bigfoot Biomedical Inc.
Obesity, Type 2 Diabetes
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight.
- Trial name
- NCT07564414
- Testing
- Cagrisema, Semaglutide
- Where
- 303 sites in United States, Argentina and 17 more
- Volunteers
- 2,500 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus
The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in…
- Trial name
- NCT01194245
- Testing
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart
- Where
- 19 sites in United States
- Volunteers
- 135 people
- Sponsor
- Halozyme Therapeutics
Weight Loss
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- VANQUISH 1 (NCT07104500)
- Testing
- VK2735
- Where
- 137 sites in United States, Puerto Rico
- Volunteers
- 4,500 people
- Sponsor
- Viking Therapeutics, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166
The purpose of this study is to evaluate pulmonary function test (PFT) sub-study in interested subjects from studies MKC-TI-161, MKC-TI-162 and MKC-TI-166. 100 Type I and 100 Type II diabetics will be enrolled.
- Trial name
- NCT01201928
- Testing
- Comparator administered in parent trial, Technosphere Insulin Inhalation Powder
- Where
- 14 sites in United States
- Volunteers
- 3 people
- Sponsor
- Mannkind Corporation
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in Subjects With Type 1 or Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to compare the efficacy of postprandial plasma glucose of two treatment regimens in Chinese subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00593255
- Testing
- soluble human insulin, insulin aspart, insulin NPH
- Where
- 5 sites in China
- Volunteers
- 220 people
- Sponsor
- Novo Nordisk A/S